Papillary and Follicular Thyroid Cancer: K. A. Ikram Hussain Final Year M.B.B.S

Download as pptx, pdf, or txt
Download as pptx, pdf, or txt
You are on page 1of 26

Papillary and follicular

thyroid cancer
K. A. Ikram Hussain
Final year M.B.B.S.
Papillary thyroid cancer

It is a relatively common well differentiated thyroid


cancer
Accounts for 85% of all thyroid cancers
It is more common in females than males
In more than 50% cases in spreads to lymphnodes of the
neck
Aetiology
Most thyroid cancers are sporadic
It can be a complication of Hashimoto’s thyroiditis
Familial and genetic syndromes are associated with
thyroid malignancies
Cowden’s syndrome
Gardner’s syndrome
Carney’s syndrome
Associated mutations: chromosomal translocations
involving RET proto-oncogene
Pathology

It is made of colloid filled follicles with papillary projections.


In some cases calcific lesions are found called psammoma bodies
Characteristic pale empty nuclei called Orphan Annie eye nuclei
are seen in some cases
Can present as cystic lesions
Can be multifocal involving both lobes
Lymph nodes and Lungs are the usual sites of metastases
Psammoma bodies
Orphan Annie eye appearance
Clinical presentation

Young females of age group 20-40 years are commonly


affected
Principal sign is a firm non tender nodule in thyroid area
with a hard consistency and ill defined borders
Signs of hoarseness, tracheal and esophagal
compression is present
Very often lymph nodes in lower deep cervical region
are involved and thyroid may or may not be palpable.
Prognostic criteria
Prognostic Risk Classification for Patients with
Well-Differentiated Thyroid Cancer (AMES or
AGES)
Low Risk Hi2h Risk
• Age <40 years >40 years
• Sex Female Male
• Extent No local extension, Capsular invasion, extra-
intrathyroid, no caps thyroidal extension
mvasion

• Metastasis None Regional/distant


• Size <2cm >4cm
• Grade Well diff Poorly diff
Investigations

Thyroid profile
Ultrasound of thyroid and central neck
Fine needle aspiration cytology of the nodule
Serum thyroglobulin
TSH suppression test
Immunohistochemisty findings

Carcinoembryonic antigen (CEA) negative


Calcitonin negative
Thyroglobulin positive
Keratin positive
Treatment
Total thyroidectomy
After thyroidectomy, patients are given thyroid replacement therapy for
approximately 4-6 weeks. Thyroid replacement is then discontinued, to induce a
hypothyroid state and promote high serum thyroid-stimulating hormone (TSH)
levels.
Approximately 4-6 weeks after surgical thyroid removal, patients may have
radioiodine therapy to detect and destroy any metastasis and residual tissue in
the thyroid
A diagnostic dose of radioiodine ( 131I I) is then given, and a whole-body
scintiscan is performed to detect or
any123
tissue taking up radioiodine. If any normal
thyroid remnant or metastatic disease is detected, a therapeutic dose of 13 I is
administered to ablate the tissue. The patient is then placed back on thyroid
1

hormone replacement (levothyroxine) therapy.


Therapy is administered until radioiodine uptake is completely absent
Long term surveillance: Thyroglobulin
Prognosis:95% adults survive over 10 years
Complications due to surgery and radio
iodine therapy
Hypothyroidism
Dysphagia
Vocal cord paralysis
Hypoparathyroidism
Sialoadenitis because radioiodine is taken up by the salivary glands
Pulmonary fibrosis in patients with large lung metastases
Brain edema in patients with brain metastases (may be prevented
by glucocorticoid therapy)
Permanent sterility and transient oligospermia or menstrual
irregularities
A small increase in the risk for leukemias or breast and bladder
carcinomas
Factors affecting poor outcome

Large primary tumor


Age > 45 years
Male sex
Lymph nodal metastases
Distant metastases
Multifocal disease
Extra-thyroidal extension
Follicular carcinoma of thyroid

It is a well differentiated tumor and 2n most common


after papillary thyroid cancer d

Incidence is 17% of cases


Follicular adenomas are 20% malignant and 80% benign
Aetiology

Follicular carcinoma usually arises in a multinodular


goitre especially in a cases of endemic goitre.
It should be suspected when multinodular goitre starts
growing rapidly
Pathology

Depending on invasion it is classified as


Noninvasive
Invasive refers to angio-invasion and capsular invasion
Angioinvasion
Clinical presentation
It can present as multinodular or solitary nodular goitre.
The diagnosis is confirmed after an ultrasound scan reveals features
of malignancy like microcalcifications
Metastasis in flat bones: when a patient with a thyroid swelling
presents with metastasis in the bone in the form of bony swelling or
pathological fractures, a diagnosis of follicular carcinoma can be
considered.
Common secondaries are flat bones like skull,ribs,sternum and
vertebral column because flat bones retain red marrow for a longer
time.
Clinical features of a secondary are: they are rapidly
growing,warm, vascular and pulsatile.
Metastasis to bone
Treatment
Treatment of primary:
Total thyroidectomy is always preferred

Treatment of the metastasis:


After total thyroidectomy a whole body scan is done to look for metastasis in
the bone. A single secondary can be treated with oral radioiodine therapy
followed by radiotherapy depending on the response to treatment
Multiple secondaries are also treated with oral radio iodine.

Postoperative thyroxine:
Postoperative period patient should receive thyroxine 0.3mg/day to suppress
TSH and to supplement thyroxine.
Prognosis: 15% mortality in 10 years.
Summary

Characteristics Papillary carcinoma Follicular carcinoma


Aetiology Sporadic/irradiation Endemic goitre
Incidence 60% 17%
Age (years) 20-40 30-50
Diagnosis Thyroid swelling with Thyroid swelling with bony
lymphnode metastasis metastasis
Microscopy Orphan Annie eye nuclei, Angioinvasion,
Psammoma bodies Capsular invasion
Spread Lymphatic Blood
Investigation FNAC Frozen section
Treatment of primary Subtotal/total Subtotal/total
thyroidectomy thyroidectomy
Treatment of metastasis Functional neck dissection Radioiodine 131 iodine
Hurthle cell carcinoma

It is a variant of follicular cell carcinoma and more aggressive than follicular


cell carcinoma
These tumors are defined by presence of more than 75% of follicular cells
with oncocytic features.
Tumor contains sheets of eosinophilic cells packed with mitochondria
They secrete thyroglobulin
Even if hurthle cell adenoma is well encapsulated it is potentially malignant.
It does not take up iodine 131. hence less likely to respond to radioablation.
Mortality is high 20% in 10 years
Criteria to diagnose

Capsular or vascular invasion and distant metastasis


Higher chance of spread to lymph nodes compared to follicular thyroid
carcinoma
Higher chances of spread to distant sites too
TREATMENT:
Total thyroidectomy is the treatment of choice.
TSH suppression and follow-up is required regularly.
Follow up

Serum thyroglobulin- thyroid is the only organ which produces thyroglobulin.


Levels greater than 1-2mg/ml in patients receiving replacement thyroxine
therapy indicates presence of metastasis.
So serum thyroglobulin response to injected recombinant TSH is assessed
every year.
Ultrasound or MRI scans of neck for localisation of residual or recurrent
tumor

You might also like